MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer. Posted on 17 dicembre 2014 MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer. Vivenza D, Gasco M, Monteverde M, Lattanzio L, Syed N, Colantonio I, Denaro N, Natoli G, Comino A, Russi E, Merlano M, Crook T, Lo Nigro C. Oral Oncol. 2012 Jul;48(7):602-7. doi: 10.1016/j.oraloncology.2012.01.022. Epub 2012 Feb 21.